Carpal Tunnel SyndromeNCT06272682
Corticosteroids in Carpal Tunnel Syndrome. Prospective Randomised Controlled Non-inferiority Study
A study testing Systemic bethametasone injection and Local bethametasone injection in people with Carpal Tunnel Syndrome, run by Hospital Italiano de Buenos Aires at 1 site in Argentina.
Trial summary
The goal of this prospective, randomised, controlled, non-inferiority analytical study is to compare the Boston score in patients treated with systemic (intramuscular) versus local infiltration corticosteroids in mild and moderate carpal tunnel syndrome in patients over 18 years of age with mild or moderate carpal… Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Carpal Tunnel Syndrome
- What is being tested?
- Systemic bethametasone injection and Local bethametasone injection
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 106 participants
- Where
- 1 siteArgentina
- Study dates
- 17 Jul 2023to 11 Oct 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients aged 18 years and older
- Clinical diagnosis of mild/moderate idiopathic Carpal Tunnel Syndrome (paresthesias in the territory of the median nerve: in fingers 1, 2, 3 and radial border of 4 of the hand, nocturnal hand pain, and Positive Tinel's test, or Positive Phalen's test, or Positive Durkan's test)
- Diagnosis by electromyography and sensory and motor conduction velocity of mild/moderate involvement
- Patients who have agreed to participate in the study and signed the informed consent form.
Who cannot join
- Cervical radiculopathy, polyneuropathy, brachial plexus pathologies, thoracic operculum syndrome
- Systemic diseases causing secondary Carpal Tunnel Syndrome (rheumatoid arthritis, diabetes with polyneuropathy, hypothyroidism with low adherence to treatment, chronic renal disease)
- Chronic corticosteroid therapy or regular use of non-steroidal anti-inflammatory drugs
- Severe carpal tunnel syndrome: signs of thenar atrophy, daytime pain, sensory deficit in median nerve territory (two-point discrimination test >10mm)
- Previous history of wrist or distal radius fracture
- Corticosteroid allergies
- Pregnancy
Trial locations and contacts
1 site in 1 country.
Argentina1 site, 1 recruiting
- Recruiting
Hospital Italiano de Buenos Aires
Buenos Aires, C1199
Jorge Boretto, MD, +541169026969, jorge.boretto@hospitalitaliano.org.ar
Rocio Avanzi, MD, +541157727055, rocio.avanzi@hospitalitaliano.org.ar
About this study
Official title: Systemic Versus Local Corticosteroids in the Treatment of Carpal Tunnel Syndrome. Prospective Randomised Controlled Non-inferiority Study.
The goal of this prospective, randomised, controlled, non-inferiority analytical study is to compare the Boston score in patients treated with systemic (intramuscular) versus local infiltration corticosteroids in mild and moderate carpal tunnel syndrome in patients over 18 years of age with mild or moderate carpal tunnel syndrome.
The main questions it aims to answer are:
Read more
- What is the effectiveness of intramuscular injection of corticosteroids compared to local infiltration in the treatment of mild/moderate carpal tunnel syndrome?
- What are the adverse effects and application site pain associated with each route of administration?
Patients who meet the inclusion criteria will be asked to participate in the study and sign an informed consent form.
The Redcap randomizer will be used to assign the patient to one of the branches.
Researchers will compare
- Branch A: patients treated with local corticosteroid infiltration in carpal tunnel under ultrasound
- Branch B: patients treated with intramuscular corticosteroid injection.
Researchers will:
- Compare Boston Carpal Tunnel Questionnaire score at 1.5 months, 3 months, 6 months and 12 months post-procedure.
- Describe adverse reactions associated with the route of administration.
- Compare the pain at the site of application associated with the route of administration.
Read the detailed description
Carpal tunnel syndrome (CTS) is the most common peripheral compressive neuropathy of the upper limb, consisting of involvement of the median nerve at the level of the carpal tunnel. It has a prevalence of 7% to 16% in the United Kingdom adult population, while in the United States between 400/500 thousand patients are treated surgically, with an annual economic cost exceeding $2 billion.
A variety of treatments are available according to the stage of the pathology, including splinting, kinesic therapy, ultrasound, non-steroidal anti-inflammatory drugs, systemic or local corticosteroids , as well as surgical treatment in patients who do not respond to previous options.
Corticosteroid infiltration is one of the most widely used methods for the treatment of idiopathic carpal tunnel syndrome (ICTS) in mild and moderate stages, and short-term symptomatic improvement is reported in the literature, although the optimal dose and drug used for the same is varied in the various published studies, and is still a matter of debate in the literature. Betamethasone has greater anti-inflammatory power and a longer duration of action at the same equivalent dose than other corticosteroids used in the treatment of CTS (prednisolone, methylprednisolone, triamcinolone, cortisone).
In addition, ultrasound-guided local infiltration helps prevent iatrogenic injury compared to anatomical repair-guided infiltration. Studies show improvement in scores assessing symptomatology, although there is no strength in determining improvement in functional and electromyographic assessment. The rate of adverse reactions with this technique is low, reported to be <0.1% for major complications, and 2% for minor complications.
The effectiveness of local and systemic corticosteroids has been demonstrated, but whether there is any difference in clinical improvement in patients between one route of administration versus the other remains a question mark.
Rationale for the study In the institution, both intramuscular and ultrasound-guided administration of systemic corticosteroids are part of standard practice, with systemic administration indicated in the trauma department and ultrasound-guided administration in the rheumatology department. Although, given that these are standard practices, retrospective evaluation of the cases could answer the objective of this study, in the review of the cases the investigators found an imbalance in the type of CTS in the cohorts treated in each department. This is mainly due to the fact that in the orthopaedics service most patients consult for CTS and in the rheumatology service, due to the speciality itself, there is a large proportion of patients with secondary CTS (rheumatoid arthritis, juvenile arthritis, gout, etc.). Because of this, and to avoid patient selection bias, the aim of this study was to compare the efficacy of systemic (intramuscular) corticosteroid treatment with local infiltration in ICTS.
The same efficacy of systemic administration (intramuscular) as local administration (via ultrasound-guided infiltration in the carpal tunnel) should reduce the cost of treatment and the complications associated with local injection. In addition, it would allow effective treatment in centres where there are no specialists trained in the ultrasound-guided infiltration technique, allowing greater generalization of the treatment.
The investigator's hypothesis is that intramuscular corticosteroid infiltration (systemic effect) offers the same results in terms of symptom improvement as locally applied corticosteroids under ultrasound.
The primary objective is to compare the Boston score in patients treated with systemic (intramuscular) versus local infiltration corticosteroids in mild and moderate ICTS at 1.5 months, 3 months, 6 months and 12 months post-procedure.
The exploratory objectives are to describe adverse reactions associated with the route of administration and to compare the pain at the site of application associated with both methods, in relation to the technique used, measured with the Visual Analogue Pain Scale (VAS).
- Conditions
- Carpal Tunnel Syndrome
- Being tested
- Systemic bethametasone injection, Local bethametasone injection
- Keywords
- clinical trial, corticosteroid infiltration, carpal tunnel syndrome, betamethasone
- Medical subject headings
- Carpal Tunnel Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Systemic bethametasone injectionProcedure or surgery
betamethasone intramuscular injection in the treatment of carpal tunnel syndrome
Local bethametasone injectionProcedure or surgery
Local betamethasone injection under ultrasound in the carpal tunnel, in the treatment of carpal tunnel syndrome
| Study group | Role | What they receive |
|---|---|---|
| Branch A: Local corticosteroid infiltration under ultrasound | Experimental | One dose. 1 ml Betamethasone acetate 6mg/2ml + Betamethasone disodium phosphate 6mg/2ml Receives: Procedure: Local bethametasone injection |
| Branch B: treated with intramuscular corticosteroid injection | Experimental | One dose. 2 ml Betamethasone acetate 6mg/2ml + Betamethasone disodium phosphate 6m/2ml. Receives: Procedure: Systemic bethametasone injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compare the Boston Carpal Tunnel Syndrome Questionnaire
Compare the Boston Carpal Tunnel Syndrome Questionnaire in patients treated with systemic (intramuscular) versus local infiltration corticosteroids
Two scales:
- Symptom severity scale (11 questions): sum of the score of each question divided by the number of questions, with the lower limit and lower severity1 , and the upper limit and higher severity 5
- Functional status scale (8 questions): sum of the score of each question divided by the number of questions, with the lower limit and lower severity 1, and the upper limit and higher severity 5.
Measured: 12 months
Secondary outcomes (2)
Adverse reactions
To describe adverse reactions associated with the route of administration.
Measured: 12 months
Pain at the site of application
To compare the pain at the site of application associated with both methods, in relation to the technique used
Visual analogue scale for pain: subjective pain scale, from 0 as the lower limit to 10 as the upper limit, where 0 is "no pain" and 10 is "the worst possible pain".
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Feb 2024
- Study start17 Jul 2023
- Primary completion11 Aug 2024 (estimated)
- Study completion11 Oct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Carpal Tunnel SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective, randomised, controlled, non-inferiority analytical study
- Masking
- None (open label)
- Enrolment
- 106 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospital Italiano de Buenos Aires
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jorge Guillermo Boretto, Hospital Italiano de Buenos Aires
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06272682
- Sponsor's protocol ID
- 6669
- Status last verified
- Feb 2024
- First submitted
- 5 Feb 2024
- Last updated
- 22 Feb 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: study that tries not to reveal the identity of the participants
Study at a glance
From the registry record, last updated by the sponsor on 22 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Systemic Versus Local Corticosteroids in the Treatment of Carpal Tunnel Syndrome. Prospective Randomised Controlled Non-inferiority Study.
- ClinicalTrials.gov ID
- NCT06272682
- Acronym / sponsor ID
- 6669
- Conditions
- Carpal Tunnel Syndrome
- Keywords
- clinical trial, corticosteroid infiltration, carpal tunnel syndrome, betamethasone
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 106 participants (estimated)
- Lead sponsor
- Hospital Italiano de Buenos AiresUniversity, hospital or other
- Study start
- 17 Jul 2023 (actual)
- Primary completion
- 11 Aug 2024 (estimated)
- Study completion
- 11 Oct 2025 (estimated)
- First posted
- 22 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this prospective, randomised, controlled, non-inferiority analytical study is to compare the Boston score in patients treated with systemic (intramuscular) versus local infiltration corticosteroids in mild and moderate carpal tunnel syndrome in patients over 18 years of age with mild or moderate carpal tunnel syndrome.
The main questions it aims to answer are:
- What is the effectiveness of intramuscular injection of corticosteroids compared to local infiltration in the treatment of mild/moderate carpal tunnel syndrome?
- What are the adverse effects and application site pain associated with each route of administration?
Patients who meet the inclusion criteria will be asked to participate in the study and sign an informed consent form.
The Redcap randomizer will be used to assign the patient to one of the branches.
Researchers will compare
- Branch A: patients treated with local corticosteroid infiltration in carpal tunnel under ultrasound
- Branch B: patients treated with intramuscular corticosteroid injection.
Researchers will:
- Compare Boston Carpal Tunnel Questionnaire score at 1.5 months, 3 months, 6 months and 12 months post-procedure.
- Describe adverse reactions associated with the route of administration.
- Compare the pain at the site of application associated with the route of administration.
Detailed description
Carpal tunnel syndrome (CTS) is the most common peripheral compressive neuropathy of the upper limb, consisting of involvement of the median nerve at the level of the carpal tunnel. It has a prevalence of 7% to 16% in the United Kingdom adult population, while in the United States between 400/500 thousand patients are treated surgically, with an annual economic cost exceeding $2 billion.
A variety of treatments are available according to the stage of the pathology, including splinting, kinesic therapy, ultrasound, non-steroidal anti-inflammatory drugs, systemic or local corticosteroids , as well as surgical treatment in patients who do not respond to previous options.
Corticosteroid infiltration is one of the most widely used methods for the treatment of idiopathic carpal tunnel syndrome (ICTS) in mild and moderate stages, and short-term symptomatic improvement is reported in the literature, although the optimal dose and drug used for the same is varied in the various published studies, and is still a matter of debate in the literature. Betamethasone has greater anti-inflammatory power and a longer duration of action at the same equivalent dose than other corticosteroids used in the treatment of CTS (prednisolone, methylprednisolone, triamcinolone, cortisone).
In addition, ultrasound-guided local infiltration helps prevent iatrogenic injury compared to anatomical repair-guided infiltration. Studies show improvement in scores assessing symptomatology, although there is no strength in determining improvement in functional and electromyographic assessment. The rate of adverse reactions with this technique is low, reported to be <0.1% for major complications, and 2% for minor complications.
The effectiveness of local and systemic corticosteroids has been demonstrated, but whether there is any difference in clinical improvement in patients between one route of administration versus the other remains a question mark.
Rationale for the study In the institution, both intramuscular and ultrasound-guided administration of systemic corticosteroids are part of standard practice, with systemic administration indicated in the trauma department and ultrasound-guided administration in the rheumatology department. Although, given that these are standard practices, retrospective evaluation of the cases could answer the objective of this study, in the review of the cases the investigators found an imbalance in the type of CTS in the cohorts treated in each department. This is mainly due to the fact that in the orthopaedics service most patients consult for CTS and in the rheumatology service, due to the speciality itself, there is a large proportion of patients with secondary CTS (rheumatoid arthritis, juvenile arthritis, gout, etc.). Because of this, and to avoid patient selection bias, the aim of this study was to compare the efficacy of systemic (intramuscular) corticosteroid treatment with local infiltration in ICTS.
The same efficacy of systemic administration (intramuscular) as local administration (via ultrasound-guided infiltration in the carpal tunnel) should reduce the cost of treatment and the complications associated with local injection. In addition, it would allow effective treatment in centres where there are no specialists trained in the ultrasound-guided infiltration technique, allowing greater generalization of the treatment.
The investigator's hypothesis is that intramuscular corticosteroid infiltration (systemic effect) offers the same results in terms of symptom improvement as locally applied corticosteroids under ultrasound.
The primary objective is to compare the Boston score in patients treated with systemic (intramuscular) versus local infiltration corticosteroids in mild and moderate ICTS at 1.5 months, 3 months, 6 months and 12 months post-procedure.
The exploratory objectives are to describe adverse reactions associated with the route of administration and to compare the pain at the site of application associated with both methods, in relation to the technique used, measured with the Visual Analogue Pain Scale (VAS).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Prospective, randomised, controlled, non-inferiority analytical study
| Arm | Type | Receives |
|---|---|---|
| Branch A: Local corticosteroid infiltration under ultrasound | Experimental | Procedure: Local bethametasone injectionOne dose. 1 ml Betamethasone acetate 6mg/2ml + Betamethasone disodium phosphate 6mg/2ml |
| Branch B: treated with intramuscular corticosteroid injection | Experimental | Procedure: Systemic bethametasone injectionOne dose. 2 ml Betamethasone acetate 6mg/2ml + Betamethasone disodium phosphate 6m/2ml. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients aged 18 years and older
- Clinical diagnosis of mild/moderate idiopathic Carpal Tunnel Syndrome (paresthesias in the territory of the median nerve: in fingers 1, 2, 3 and radial border of 4 of the hand, nocturnal hand pain, and Positive Tinel's test, or Positive Phalen's test, or Positive Durkan's test)
- Diagnosis by electromyography and sensory and motor conduction velocity of mild/moderate involvement
- Patients who have agreed to participate in the study and signed the informed consent form.
Key exclusion criteria (7 listed)
- Cervical radiculopathy, polyneuropathy, brachial plexus pathologies, thoracic operculum syndrome
- Systemic diseases causing secondary Carpal Tunnel Syndrome (rheumatoid arthritis, diabetes with polyneuropathy, hypothyroidism with low adherence to treatment, chronic renal disease)
- Chronic corticosteroid therapy or regular use of non-steroidal anti-inflammatory drugs
- Severe carpal tunnel syndrome: signs of thenar atrophy, daytime pain, sensory deficit in median nerve territory (two-point discrimination test >10mm)
- Previous history of wrist or distal radius fracture
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Systemic bethametasone injectionbetamethasone intramuscular injection in the treatment of carpal tunnel syndrome | Procedure or surgery | Branch B: treated with intramuscular corticosteroid injection |
| Local bethametasone injectionLocal betamethasone injection under ultrasound in the carpal tunnel, in the treatment of carpal tunnel syndrome | Procedure or surgery | Branch A: Local corticosteroid infiltration under ultrasound |
Primary outcome
Compare the Boston Carpal Tunnel Syndrome Questionnaire
Time frame: 12 months
Compare the Boston Carpal Tunnel Syndrome Questionnaire in patients treated with systemic (intramuscular) versus local infiltration corticosteroids Two scales: * Symptom severity scale (11 questions): sum of the score of each question divided by the number of questions, with the lower limit and lower severity1 , and the upper limit and higher severity 5 * Functional status scale (8 questions): sum of the score of each question divided by the number of questions, with the lower limit and lower severity 1, and the upper limit and higher severity 5.
2 secondary outcomes
Adverse reactions
Time frame: 12 months
Pain at the site of application
Time frame: 12 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Feb 2024.
- Individual participant dataSharing planned: No. study that tries not to reveal the identity of the participants
Related trials for Carpal Tunnel Syndrome
Not yet recruitingObservational study
Postural Control and Balance Performance in Patients With Carpal Tunnel Syndrome
Carpal Tunnel Syndrome (CTS), Postural Assessment
Recruiting
Comparison of Wrist Splint Positions in Carpal Tunnel Syndrome
Carpal Tunnel Syndrome (CTS), Peripheral Neuropathies
Recruiting
Effects of Repetitive Peripheral Magnetic Stimulation(rPMS) on CTS(Carpal Tunnel Syndrome)
Carpal Tunnel Syndrome (CTS)
Recruiting
Hand Function Outcome After the Application of Transfer Energy Capacitive and Resistive on Post-burn Patients Presented With Carpal Tunnel Syndrome
Carpal Tunnel Syndrome (CTS) Post-burn
Not yet recruiting
Effect of Progressive Gamified Motor Rehabilitation After Carpal Tunnel Release
Carpal Tunnel Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Systemic bethametasone injection and Local bethametasone injection in people with Carpal Tunnel Syndrome, run by Hospital Italiano de Buenos Aires at 1 site in Argentina.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 22 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Argentina. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compare the Boston Carpal Tunnel Syndrome Questionnaire (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Feb 2024.